The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. CRISPR Therapeutics AG shares valued at $313,948 were purchased by Greene John on Feb 26 ’25. At $44.85 per share, Greene John acquired 7,000 shares. The insider’s holdings grew to 7,000 shares worth approximately $0.3 million following the completion of this transaction.
Also, Kulkarni Samarth sold 18,360 shares, netting a total of over 1,013,564 in proceeds. Following the sale of shares at $55.20 each, the insider now holds 171,613 shares.
Before that, Kulkarni Samarth had sold 11,640 shares from its account. In a trade valued at $640,782, the Chief Executive Officer traded CRISPR Therapeutics AG shares for $55.05 each. Upon closing the transaction, the insider’s holdings decreased to 11,640 shares, worth approximately $8.53 million.
As published in a research note from Evercore ISI on February 14, 2025, CRISPR Therapeutics AG [CRSP] has been rated up from an In-line to an Outperform and the price target has been revised to $99 from $60. Analysts at TD Cowen upgraded the stock from ‘”a Sell”‘ to ‘”a Hold”‘ outlook in a report released in mid February. As of February 03, 2025, H.C. Wainwright has initiated its “Buy” rating for CRSP. Earlier on August 06, 2024, Needham resumed its rating. Their recommendation was “a Buy” for CRSP stock.
Analyzing CRSP Stock Performance
During the last five days, there has been a drop of approximately -0.71%. Over the course of the year, CRISPR Therapeutics AG shares have jumped approximately 10.04%. Shares of the company reached a 52-week high of $55.88 on 02/19/25 and a 52-week low of $36.52 on 01/13/25. A 50-day SMA is recorded $42.52, while a 200-day SMA reached $48.96.
Support And Resistance Levels for CRISPR Therapeutics AG (CRSP)
According to the 24-hour chart, there is a support level at 41.98, which, if violated, would cause prices to drop to 40.65. In the upper region, resistance lies at 44.19. The next price resistance is at 45.07. RSI (Relative Strength Index) is 47.42 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -2.84, which suggests the price will decrease in the coming days. Percent R is at 81.84%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
